vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $16.1M, roughly 1.7× Journey Medical Corp). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -7.8%, a 47.0% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 16.6%). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
DERM vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $26.9M |
| Net Profit | $-1.2M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 50.0% |
| Net Margin | -7.8% | 39.2% |
| Revenue YoY | 27.3% | 16.6% |
| Net Profit YoY | -182.0% | 34.8% |
| EPS (diluted) | $-0.04 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $16.1M | $24.2M | ||
| Q3 25 | $17.0M | $25.0M | ||
| Q2 25 | $15.0M | $23.8M | ||
| Q1 25 | $13.1M | $23.1M | ||
| Q4 24 | $12.6M | $20.9M | ||
| Q3 24 | $14.6M | $20.3M | ||
| Q2 24 | $14.9M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-1.2M | $7.4M | ||
| Q3 25 | $-2.3M | $9.3M | ||
| Q2 25 | $-3.8M | $8.0M | ||
| Q1 25 | $-4.1M | $7.8M | ||
| Q4 24 | $1.5M | $7.1M | ||
| Q3 24 | $-2.4M | $6.0M | ||
| Q2 24 | $-3.4M | $5.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — |
| Q1 26 | — | 50.0% | ||
| Q4 25 | -2.8% | 39.6% | ||
| Q3 25 | -9.0% | 45.8% | ||
| Q2 25 | -19.2% | 43.4% | ||
| Q1 25 | -25.3% | 43.4% | ||
| Q4 24 | 17.7% | 30.9% | ||
| Q3 24 | -19.8% | 36.6% | ||
| Q2 24 | -19.7% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -7.8% | 30.7% | ||
| Q3 25 | -13.6% | 37.3% | ||
| Q2 25 | -25.3% | 33.5% | ||
| Q1 25 | -31.0% | 34.0% | ||
| Q4 24 | 12.1% | 34.0% | ||
| Q3 24 | -16.3% | 29.3% | ||
| Q2 24 | -22.6% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.04 | $0.44 | ||
| Q3 25 | $-0.09 | $0.55 | ||
| Q2 25 | $-0.16 | $0.47 | ||
| Q1 25 | $-0.18 | $0.46 | ||
| Q4 24 | $0.10 | $0.41 | ||
| Q3 24 | $-0.12 | $0.35 | ||
| Q2 24 | $-0.17 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $362.0M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $270.7M |
| Total Assets | $94.6M | $4.0B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $24.1M | $471.1M | ||
| Q3 25 | $24.9M | $232.9M | ||
| Q2 25 | $20.3M | $345.2M | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | $243.5M | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $31.9M | $266.0M | ||
| Q3 25 | $25.9M | $255.1M | ||
| Q2 25 | $19.2M | $240.9M | ||
| Q1 25 | $21.5M | $237.9M | ||
| Q4 24 | $20.1M | $227.9M | ||
| Q3 24 | $10.9M | $235.4M | ||
| Q2 24 | $11.3M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $94.6M | $4.1B | ||
| Q3 25 | $85.2M | $4.0B | ||
| Q2 25 | $81.2M | $4.1B | ||
| Q1 25 | $85.0M | $4.0B | ||
| Q4 24 | $80.2M | $4.0B | ||
| Q3 24 | $64.0M | $4.0B | ||
| Q2 24 | $65.2M | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $12.9M |
| Free Cash FlowOCF − Capex | — | $12.4M |
| FCF MarginFCF / Revenue | — | 46.0% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-6.3M | $46.5M | ||
| Q3 25 | $-2.4M | $11.4M | ||
| Q2 25 | $-942.0K | $13.5M | ||
| Q1 25 | $-2.8M | $9.7M | ||
| Q4 24 | $2.2M | $39.8M | ||
| Q3 24 | $-1.2M | $12.9M | ||
| Q2 24 | $-5.2M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | — | $43.2M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | — | 178.3% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 53.6% | ||
| Q1 25 | — | 35.7% | ||
| Q4 24 | — | 65.6% | ||
| Q3 24 | — | 34.2% | ||
| Q2 24 | — | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | — | 125.3% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | — | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | 1.46× | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
WTBA
Segment breakdown not available.
